Fighting Cancer with Bacteria and Their Toxins

Trivanović, Dragan; Pavelić, Krešimir; Peršurić, Željka

doi:10.3390/ijms222312980

Cited by 19 publications

(8 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The protein spike is expected to have a negative effect on the outcome of the disease and on the tumor itself. Herein, we should bear in mind that one of the strategies to combat cancer is the introduction of a virus [ 92 ] or bacteria [ 93 ] into the cell and, consequently, the cytopathic effect on the tumor.…”

Section: Discussion and Open Questionsmentioning

confidence: 99%

The Interplay of Lung Cancer, COVID-19, and Vaccines

Trivanović

Peršurić

Agaj

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

Patients with cancer are more susceptible to a higher risk of coronavirus infection and its severe complications than the general population. In addition, these patients were not included in the pivotal clinical trials for COVID-19 vaccines. Therefore, considerable uncertainty remains regarding the management of cancer patients during the COVID-19 pandemic and the safety of COVID-19 vaccinations in cancer patients. In this review, we summarize the current knowledge generated from the beginning of the COVID-19 pandemic on the vulnerability of cancer patients to the coronavirus disease, as well as the effectiveness of COVID-19 vaccines in this population. We also discuss the available data on the effects of anticancer treatment with immune checkpoint inhibitors on the immune responses to SARS-CoV-2 in cancer patients. Special attention in this review will be given to patients with lung cancer, as such patients are at an increased risk for severe effects from COVID-19.

show abstract

Section: Discussion and Open Questionsmentioning

confidence: 99%

The Interplay of Lung Cancer, COVID-19, and Vaccines

Trivanović

Peršurić

Agaj

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…The role of bacteria as anti-cancer agents was first identified by German physicians W. Busch and F. Fehleisen who observed tumor regression in the cancer patients suffered from erysipelas caused by Streptococcus pyogenes infection ( 34 ). In 1891, William Coley, an American surgeon, inoculated cancer patients with S. pyogenes , which was the first time that bacteria were used to treat cancer ( 35 ).…”

Section: Live Attenuated or Inactivated P Aeruginosa ...mentioning

confidence: 99%

Pseudomonas aeruginosa in Cancer Therapy: Current Knowledge, Challenges and Future Perspectives

2022

View full text Add to dashboard Cite

Drug resistance, undesirable toxicity and lack of selectivity are the major challenges of conventional cancer therapies, which cause poor clinical outcomes and high mortality in many cancer patients. Development of alternative cancer therapeutics are highly required for the patients who are resistant to the conventional cancer therapies, including radiotherapy and chemotherapy. The success of a new cancer therapy depends on its high specificity to cancer cells and low toxicity to normal cells. Utilization of bacteria has emerged as a promising strategy for cancer treatment. Attenuated or genetically modified bacteria were used to inhibit tumor growth, modulate host immunity, or deliver anti-tumor agents. The bacteria-derived immunotoxins were capable of destructing tumors with high specificity. These bacteria-based strategies for cancer treatment have shown potent anti-tumor effects both in vivo and in vitro, and some of them have proceeded to clinical trials. Pseudomonas aeruginosa, a Gram-negative bacterial pathogen, is one of the common bacteria used in development of bacteria-based cancer therapy, particularly known for the Pseudomonas exotoxin A-based immunotoxins, which have shown remarkable anti-tumor efficacy and specificity. This review concisely summarizes the current knowledge regarding the utilization of P. aeruginosa in cancer treatment, and discusses the challenges and future perspectives of the P. aeruginosa-based therapeutic strategies.

show abstract

“…[161][162][163] Additionally, lipopolysaccharides (LPS) and flagellin, which are major components of bacteria, play critical roles in inducing the host immune response in the process of bacterial infection and the anti-tumor immune response. 157,162,[164][165][166][167] Because the bacterial membrane has the same properties as bacteria, researchers are trying to develop bacterial membrane-based nanomaterials for tumor therapy. Generally speaking, owing to the existence of pathogen-associated molecular patterns (PAMPs) on bacterial membranes, these membranes-based nanomaterials have been mainly administered via local injection to enhance cancer immunotherapy.…”

Section: Bacterial Membrane-based Nanomaterials For Cancer Therapymentioning

confidence: 99%